Treatment with Tumor-Treating Fields Therapy and Pulse Dose Bevacizumab in Patients with Bevacizumab-Refractory Recurrent Glioblastoma: A Case Series

Treatment with Tumor-Treating Fields Therapy and Pulse Dose Bevacizumab in Patients with Bevacizumab-Refractory Recurrent Glioblastoma: A Case Series

Patients with bevacizumab-refractory recurrent glioblastoma multiforme (GBM) have a poor prognosis. We propose that instead of continuing on bevacizumab, patients should switch to treatment with Optune™, a novel antimitotic Tumor-Treating Fields (TTFields) therapy approved in the United States for n...

Full description

Bibliographic Details
Main Authors: George Ansstas, David D. Tran
Format: Article
Language:English
Published: Karger Publishers 2016-01-01
Series:Case Reports in Neurology
Subjects:
Novocure
Optune&x2122;
Glioblastoma
Bevacizumab
TTFields
Online Access:http://www.karger.com/Article/FullText/442196

Similar Items

Similar Items